Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346006 | 0.93 | ELANE (0.39) | ELANEPPARAATML3MBTL1CYP19A1 | |
| SCHEMBL6347057 | 0.92 | L3MBTL1 (0.37) | ELANEPPARAATML3MBTL1CYP19A1 | |
| SCHEMBL6344067 | 0.84 | ELANE (0.47) | ELANEPPARAATML3MBTL1MAPT | |
| SCHEMBL3284016 | 0.84 | ELANE (0.40) | ELANEPPARAATML3MBTL1CYP19A1 | |
| SCHEMBL6182133 | 0.83 | ELANE (0.39) | ELANEPPARAATML3MBTL1CYP19A1 | |
| SCHEMBL6345423 | 0.82 | BHMT (0.39) | ELANEPPARAATML3MBTL1CYP19A1 | |
| SCHEMBL6699922 | 0.81 | ELANE (0.38) | ELANEPPARAATML3MBTL1CYP19A1 | |
| SCHEMBL3286486 | 0.79 | ELANE (0.40) | ELANEPPARAATML3MBTL1CYP19A1 | |
| SCHEMBL6344409 | 0.79 | ALDH1A1 (0.40) | PPARAL3MBTL1ALDH1A1LMNARAB9A | |
| SCHEMBL6346743 | 0.79 | ELANE (0.49) | ELANEPPARAATML3MBTL1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004532799-A | — | — | 2004-10-28 | — | — | JP | claimed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, IAPP, STS | ELANE 601/4885PPARA 62/4885ATM 421/4885 |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | ELANE 779/4885PPARA 56/4885ATM 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.